BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
BioLife Solutions, a key player in the cell and gene therapy (CGT) market, has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company, which specializes in bioproduction products and services, will release its Q1 2025 results after market close on Thursday, May 8, 2025.
The company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) on the same day. Management will present the financial results and provide a business update. Investors and interested parties can access the webcast through the company's Investor Relations page or join via phone using the toll-free numbers: 1-877-344-7529 (domestic) or 1-412-317-0088 (international).
A replay of the webcast will be available approximately two hours after the call and will remain accessible on the investor relations website for 90 days.
BioLife Solutions, un attore chiave nel mercato della terapia cellulare e genica (CGT), ha annunciato la pubblicazione dei risultati finanziari del primo trimestre 2025 e il calendario della conference call. L'azienda, specializzata in prodotti e servizi per la bioproduzione, pubblicherà i risultati del Q1 2025 dopo la chiusura del mercato, giovedì 8 maggio 2025.
La società terrà una conference call e una diretta webcast alle 16:30 ET (13:30 PT) nello stesso giorno. Il management presenterà i risultati finanziari e fornirà un aggiornamento sull’andamento aziendale. Investitori e interessati potranno seguire la webcast tramite la pagina Investor Relations dell’azienda o partecipare telefonicamente utilizzando i numeri verdi: 1-877-344-7529 (nazionale) o 1-412-317-0088 (internazionale).
La registrazione della webcast sarà disponibile circa due ore dopo la chiamata e resterà accessibile sul sito delle relazioni con gli investitori per 90 giorni.
BioLife Solutions, un actor clave en el mercado de terapia celular y génica (CGT), ha anunciado la publicación de sus resultados financieros del primer trimestre de 2025 y el calendario de su conferencia telefónica. La empresa, especializada en productos y servicios de bioproducción, publicará los resultados del Q1 2025 tras el cierre del mercado el jueves 8 de mayo de 2025.
La compañía realizará una conferencia telefónica y una transmisión en vivo a las 4:30 pm ET (1:30 pm PT) ese mismo día. La dirección presentará los resultados financieros y ofrecerá una actualización del negocio. Los inversores y partes interesadas podrán acceder a la transmisión a través de la página de Relaciones con Inversores de la empresa o participar por teléfono usando los números gratuitos: 1-877-344-7529 (doméstico) o 1-412-317-0088 (internacional).
La repetición de la transmisión estará disponible aproximadamente dos horas después de la llamada y permanecerá accesible en el sitio web de relaciones con inversores durante 90 días.
BioLife Solutions는 세포 및 유전자 치료(CGT) 시장의 핵심 기업으로서 2025년 1분기 실적 발표 및 컨퍼런스 콜 일정을 발표했습니다. 생물생산 제품 및 서비스를 전문으로 하는 이 회사는 2025년 5월 8일 목요일 장 마감 후 2025년 1분기 실적을 공개할 예정입니다.
같은 날 동부시간 오후 4시 30분(서부시간 오후 1시 30분)에 컨퍼런스 콜과 라이브 웹캐스트를 진행합니다. 경영진이 재무 결과를 발표하고 사업 현황을 업데이트할 예정입니다. 투자자와 관심 있는 분들은 회사의 투자자 관계 페이지를 통해 웹캐스트에 접속하거나 국내 무료전화 1-877-344-7529, 국제전화 1-412-317-0088로 전화 참여할 수 있습니다.
웹캐스트 녹화는 콜 종료 약 2시간 후에 제공되며, 투자자 관계 웹사이트에서 90일간 시청할 수 있습니다.
BioLife Solutions, un acteur clé du marché de la thérapie cellulaire et génique (CGT), a annoncé la publication prochaine de ses résultats financiers du premier trimestre 2025 ainsi que le calendrier de sa conférence téléphonique. L’entreprise, spécialisée dans les produits et services de bioproduction, publiera ses résultats du T1 2025 après la clôture des marchés, le jeudi 8 mai 2025.
La société organisera une conférence téléphonique et une webdiffusion en direct à 16h30 ET (13h30 PT) le même jour. La direction présentera les résultats financiers et fournira une mise à jour commerciale. Les investisseurs et parties intéressées pourront accéder à la diffusion en direct via la page Relations Investisseurs de l’entreprise ou participer par téléphone en utilisant les numéros gratuits : 1-877-344-7529 (domestique) ou 1-412-317-0088 (international).
Un replay de la webdiffusion sera disponible environ deux heures après l’appel et restera accessible sur le site des relations investisseurs pendant 90 jours.
BioLife Solutions, ein wichtiger Akteur im Markt für Zell- und Gentherapie (CGT), hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 und den Zeitplan für die Telefonkonferenz angekündigt. Das Unternehmen, das sich auf Bioproduktionsprodukte und -dienstleistungen spezialisiert hat, wird die Ergebnisse für Q1 2025 am Donnerstag, den 8. Mai 2025 nach Börsenschluss veröffentlichen.
Am selben Tag findet um 16:30 Uhr ET (13:30 Uhr PT) eine Telefonkonferenz und ein Live-Webcast statt. Das Management wird die Finanzergebnisse präsentieren und ein Geschäftsupdate geben. Investoren und Interessierte können den Webcast über die Investor-Relations-Seite des Unternehmens verfolgen oder telefonisch über die gebührenfreien Nummern 1-877-344-7529 (inländisch) oder 1-412-317-0088 (international) teilnehmen.
Eine Aufzeichnung des Webcasts wird etwa zwei Stunden nach der Telefonkonferenz verfügbar sein und für 90 Tage auf der Investor-Relations-Website abrufbar bleiben.
- BioLife maintains its position as a leading supplier in the growing cell and gene therapy market
- None.
To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-877-344-7529 or 1-412-317-0088 for international callers. A webcast replay will be available approximately two hours after the call and will be archived on https://investors.biolifesolutions.com for 90 days.
About BioLife Solutions
BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.
Media & Investor Relations | ||
At the Company Troy Wichterman | ||
Chief Financial Officer | ||
(425) 402-1400 | ||
twichterman@biolifesolutions.com
Investors Alliance Advisors IR Jody Cain (310) 691-7100 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-to-report-first-quarter-2025-financial-results-and-business-update-on-may-8-2025-302441713.html
SOURCE BioLife Solutions, Inc.
FAQ
When will BioLife Solutions (BLFS) release Q1 2025 earnings?
How can investors join BioLife Solutions Q1 2025 earnings call?
Where can I find the replay of BLFS Q1 2025 earnings webcast?
What market does BioLife Solutions (BLFS) serve?
What time is BioLife Solutions (BLFS) Q1 2025 earnings call?
